3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Sponsor Class
OTHER
10
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Melanoma
4
Polycythemia Vera
1
Neoplasms
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Interventions
nilotinib
50
Imatinib Mesylate
48
Dasatinib
25
bosutinib
18
asciminib
17
ponatinib
10
Homoharringtonine
5
Cytarabine
4
olverembatinib
3
Interferon-alpha
3
Decitabine
3
tozasertib
2
peginterferon alfa-2a
2
flumatinib
2
fludarabine phosphate
2
ON 01910
2
Mycophenolic Acid
2
Melphalan
2
Interferon alpha-2
2
Filgrastim
2
Cyclophosphamide
2
Bone Marrow Transplantation
2
BID protein, human
2
Azacitidine
2
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide
2
vosaroxin
1
troxacitabine
1
triciribine
1
terameprocol
1
sonidegib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
peginterferon alfa-2b
×
Clear all
NCT03547154
2019-08-12
C98026
Merck Sharp & Dohme LLC
Phase 2/3
Terminated
344 enrolled
11 charts